Developer docs
API playgroundTry for free, no card

Search company profiles

Genkyotex

Full company profile

uuid0006bxp

Namestring
Genkyotex
Legal namestring
Calliditas Therapeutics AB
Websiteurl
genkyotex.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Genkyotex is a clinical-stage biopharmaceutical company that develops small-molecule inhibitors of NOX enzymes, the family of enzymes responsible for producing oxygen radicals implicated in fibrotic disease. Founded in 2006 and based in Geneva, Switzerland, the company's lead asset is setanaxib, a NOX enzyme inhibitor positioned as a 'pipeline in a product' for fibrotic rare diseases and solid tumors across four indications: Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN). The asset has been administered to more than 320 subjects across completed Phase 1 and Phase 2 clinical trials, building an extensive safety dataset.

The business has secured Orphan Drug Designation from both the FDA and EMA for setanaxib in PBC, IPF, and Alport Syndrome, and Fast Track Designation from the FDA for PBC, with global rights to the asset held by the Calliditas Therapeutics AB entity that has become the corporate successor. The solid tumor (SCCHN) indication is positioned for out-licensing, while rare-disease indications are being advanced through ongoing Phase 2b (PBC), investigator-led Phase 2 (IPF), and Phase 2 proof-of-concept (Alport) trials, with multiple data readouts scheduled across 2024 and 2025. The company has financed development through at least eight funding rounds since inception, including a Series C of roughly $25.6M in 2012, and acquired Genticel in February 2017 to expand its pipeline.

As a pre-revenue clinical-stage developer, Genkyotex has no commercial product, no disclosed paying customers, and no disclosed pricing or revenue mechanics. Future revenue, if and when setanaxib is approved, would flow through regulatory-approved commercial channels for rare-disease therapeutics, and potentially through a licensing partner for the SCCHN oncology indication. The current business model is therefore defined by capital-intensive clinical development, regulatory designation accumulation, and pending clinical de-risking events rather than product sales.

Short descriptiontext

Genkyotex is a clinical-stage biopharmaceutical company developing setanaxib, a NOX enzyme inhibitor for fibrotic rare diseases (PBC, IPF, Alport Syndrome) and solid tumors, holding global rights and multiple FDA/EMA orphan drug designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
NOX enzyme inhibitors, fibrosis drug development, rare disease therapeutics, clinical stage biopharmaceutical, orphan drug development
Industry1 code
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceuticals
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Genkyotex develops Setanaxib, a NOX enzyme inhibitor being developed as a clinical-stage pipeline product for fibrotic rare diseases and solid tumors. The compound is being advanced across multiple indications including Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN), with global rights held across all indications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Setanaxib
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pliant is a clinical-stage fibrosis biotech with bexotegrast (Phase 2b/3 in IPF) targeting exactly the same indications as setanaxib. Both companies apply novel mechanisms to fibrotic rare diseases with similar regulatory strategies (ODD pursuit) and similar stages of clinical development.

TypeDirect peer
Description

Madrigal's resmetirom (Rezdiffra) is the first FDA-approved therapy for MASH liver fibrosis, demonstrating commercial viability of fibrosis-targeted therapies in liver disease. Highly comparable to setanaxib's liver-fibrosis (PBC) positioning on patient population, prescriber base, and regulatory pathway.

TypeDirect peer
Description

Intercept's Ocaliva (obeticholic acid) is the leading approved second-line therapy for Primary Biliary Cholangitis — the same lead indication Genkyotex's setanaxib targets. As the only direct head-to-head competitor in PBC, Intercept is the closest comparable on commercial economics, regulatory positioning, and patient population overlap.

TypeDirect peer
Description

Inventiva's lead asset lanifibranor is in development for MASH and previously for PBC, giving it near-direct overlap with setanaxib's fibrosis / rare-disease liver strategy. Both are clinical-stage European-headquartered small-molecule fibrosis biotechs with comparable size and capital structure.

TypeDirect peer
Description

FibroGen's pamrevlumab targets IPF and other fibrotic indications (Duchenne muscular dystrophy, pancreatic cancer), creating direct overlap with setanaxib's fibrosis pipeline. Comparable in mechanism novelty, ODD pursuit, and target-patient focus despite FibroGen being broader in scope.

TypeDirect peer
Description

CymaBay's seladelpar (now FDA-approved as Livdelzi) is a direct PBC competitor targeting second-line PBC patients — the same clinical positioning setanaxib is pursuing. Its acquisition by Gilead for ~$4.3B is a useful reference point for the strategic value of a successful PBC pipeline asset.

TypeEmerging player
Description

Galapagos developed ziritaxestat and other IPF/fibrosis assets, directly overlapping with setanaxib's fibrosis pipeline. While it terminated some programs post-2022 setbacks, its fibrosis R&D focus and European clinical-stage footprint make it a structurally comparable peer in the rare-disease fibrosis arena.

TypeBroad incumbent
Description

Roche's Esbriet (pirfenidone) is — together with OFEV — one of two approved IPF therapies and an unavoidable incumbent in any IPF commercial strategy. Roche's fibrosis portfolio also extends into additional fibrotic indications, making it the widest competitor to setanaxib's fibrosis positioning.

9Boehringer Ingelheim
TypeBroad incumbent
Description

Boehringer's OFEV (nintedanib) is the standard-of-care therapy in IPF — the same indication setanaxib is targeting. As the entrenched incumbent with established formulary access and physician familiarity, BI defines the competitive landscape setanaxib must enter and represents the gold-standard benchmark for any new IPF readout.

TypeOthers
Description

Calliditas is the acquirer/integrator that has acquired or is acquiring Genkyotex per the recommended offer on calliditas.se, and now controls setanaxib's global rights. While Calliditas is the parent corporate entity, its approved TARPEYO franchise and IgA nephropathy focus sit adjacent to setanaxib's rare-disease scope rather than in direct competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genkyotex

Clinical-stage biopharmaceuticalsgenkyotex.com

Genkyotex is a clinical-stage biopharmaceutical company developing setanaxib, a NOX enzyme inhibitor for fibrotic rare diseases (PBC, IPF, Alport Syndrome) and solid tumors, holding global rights and multiple FDA/EMA orphan drug designations.

What Genkyotex does

Genkyotex is a clinical-stage biopharmaceutical company that develops small-molecule inhibitors of NOX enzymes, the family of enzymes responsible for producing oxygen radicals implicated in fibrotic disease. Founded in 2006 and based in Geneva, Switzerland, the company's lead asset is setanaxib, a NOX enzyme inhibitor positioned as a 'pipeline in a product' for fibrotic rare diseases and solid tumors across four indications: Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN). The asset has been administered to more than 320 subjects across completed Phase 1 and Phase 2 clinical trials, building an extensive safety dataset.

The business has secured Orphan Drug Designation from both the FDA and EMA for setanaxib in PBC, IPF, and Alport Syndrome, and Fast Track Designation from the FDA for PBC, with global rights to the asset held by the Calliditas Therapeutics AB entity that has become the corporate successor. The solid tumor (SCCHN) indication is positioned for out-licensing, while rare-disease indications are being advanced through ongoing Phase 2b (PBC), investigator-led Phase 2 (IPF), and Phase 2 proof-of-concept (Alport) trials, with multiple data readouts scheduled across 2024 and 2025. The company has financed development through at least eight funding rounds since inception, including a Series C of roughly $25.6M in 2012, and acquired Genticel in February 2017 to expand its pipeline.

As a pre-revenue clinical-stage developer, Genkyotex has no commercial product, no disclosed paying customers, and no disclosed pricing or revenue mechanics. Future revenue, if and when setanaxib is approved, would flow through regulatory-approved commercial channels for rare-disease therapeutics, and potentially through a licensing partner for the SCCHN oncology indication. The current business model is therefore defined by capital-intensive clinical development, regulatory designation accumulation, and pending clinical de-risking events rather than product sales.

Genkyotex firmographics

Firmographics
Name
Genkyotex
Legal name
Calliditas Therapeutics AB
Website
https://genkyotex.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Genkyotex is a clinical-stage biopharmaceutical company developing setanaxib, a NOX enzyme inhibitor for fibrotic rare diseases (PBC, IPF, Alport Syndrome) and solid tumors, holding global rights and multiple FDA/EMA orphan drug designations.
Ownership category
akta.pro rank

Genkyotex industry classification

Industry
Product category
Clinical-stage biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • NOX enzyme inhibitors
  • Fibrosis drug development
  • Rare disease therapeutics
  • Clinical stage biopharmaceutical
  • Orphan drug development

Where Genkyotex is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

Genkyotex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Genkyotex product offering

Product offering

Core offering

Genkyotex develops Setanaxib, a NOX enzyme inhibitor being developed as a clinical-stage pipeline product for fibrotic rare diseases and solid tumors. The compound is being advanced across multiple indications including Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN), with global rights held across all indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Setanaxib

Companies that use Genkyotex

Customer profile

Segments1 record

Ideal customer profiles1 record

Genkyotex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Genkyotex partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Genkyotex competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Pliant is a clinical-stage fibrosis biotech with bexotegrast (Phase 2b/3 in IPF) targeting exactly the same indications as setanaxib. Both companies apply novel mechanisms to fibrotic rare diseases with similar regulatory strategies (ODD pursuit) and similar stages of clinical development.
  • Madrigal Pharmaceuticals: Madrigal's resmetirom (Rezdiffra) is the first FDA-approved therapy for MASH liver fibrosis, demonstrating commercial viability of fibrosis-targeted therapies in liver disease. Highly comparable to setanaxib's liver-fibrosis (PBC) positioning on patient population, prescriber base, and regulatory pathway.
  • Intercept Pharmaceuticals: Intercept's Ocaliva (obeticholic acid) is the leading approved second-line therapy for Primary Biliary Cholangitis — the same lead indication Genkyotex's setanaxib targets. As the only direct head-to-head competitor in PBC, Intercept is the closest comparable on commercial economics, regulatory positioning, and patient population overlap.
  • Inventiva: Inventiva's lead asset lanifibranor is in development for MASH and previously for PBC, giving it near-direct overlap with setanaxib's fibrosis / rare-disease liver strategy. Both are clinical-stage European-headquartered small-molecule fibrosis biotechs with comparable size and capital structure.
  • FibroGen: FibroGen's pamrevlumab targets IPF and other fibrotic indications (Duchenne muscular dystrophy, pancreatic cancer), creating direct overlap with setanaxib's fibrosis pipeline. Comparable in mechanism novelty, ODD pursuit, and target-patient focus despite FibroGen being broader in scope.
  • CymaBay Therapeutics (Gilead): CymaBay's seladelpar (now FDA-approved as Livdelzi) is a direct PBC competitor targeting second-line PBC patients — the same clinical positioning setanaxib is pursuing. Its acquisition by Gilead for ~$4.3B is a useful reference point for the strategic value of a successful PBC pipeline asset.

Emerging players

  • Galapagos NV: Galapagos developed ziritaxestat and other IPF/fibrosis assets, directly overlapping with setanaxib's fibrosis pipeline. While it terminated some programs post-2022 setbacks, its fibrosis R&D focus and European clinical-stage footprint make it a structurally comparable peer in the rare-disease fibrosis arena.

Broad incumbents

  • Roche / Genentech: Roche's Esbriet (pirfenidone) is — together with OFEV — one of two approved IPF therapies and an unavoidable incumbent in any IPF commercial strategy. Roche's fibrosis portfolio also extends into additional fibrotic indications, making it the widest competitor to setanaxib's fibrosis positioning.
  • Boehringer Ingelheim: Boehringer's OFEV (nintedanib) is the standard-of-care therapy in IPF — the same indication setanaxib is targeting. As the entrenched incumbent with established formulary access and physician familiarity, BI defines the competitive landscape setanaxib must enter and represents the gold-standard benchmark for any new IPF readout.

Others

  • Calliditas Therapeutics AB: Calliditas is the acquirer/integrator that has acquired or is acquiring Genkyotex per the recommended offer on calliditas.se, and now controls setanaxib's global rights. While Calliditas is the parent corporate entity, its approved TARPEYO franchise and IgA nephropathy focus sit adjacent to setanaxib's rare-disease scope rather than in direct competition.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Genkyotex social profiles

Digital presence

Genkyotex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genkyotex leadership team

Management profile

Number of profiles

Profiles3 records

Genkyotex funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genkyotex M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genkyotex

What does Genkyotex do?

Genkyotex develops Setanaxib, a NOX enzyme inhibitor being developed as a clinical-stage pipeline product for fibrotic rare diseases and solid tumors. The compound is being advanced across multiple indications including Primary Biliary Cholangitis (PBC), Idiopathic Pulmonary Fibrosis (IPF), Alport Syndrome, and Solid Tumors (SCCHN), with global rights held across all indications.

Is Genkyotex a public or private company?

Genkyotex is a private company. It is classified as public and is currently operating.

When was Genkyotex founded?

Genkyotex was founded in 2006. It employs 1 to 10 people.

Where is Genkyotex based?

Genkyotex is headquartered in Stockholm, Sweden, in the Europe region.

Who are Genkyotex's main competitors?

Direct peers on record are Pliant Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Inventiva, FibroGen and CymaBay Therapeutics (Gilead). Galapagos NV is listed as an emerging player. Broad incumbents are Roche / Genentech and Boehringer Ingelheim. Calliditas Therapeutics AB is listed as an others.

Does Genkyotex have an API?

No public API is recorded for Genkyotex.

What industry is Genkyotex in?

Genkyotex's product category is Clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCalliditas Takes 100% Control Of GenkyotexCalliditas completed a centralized squeeze-out of Genkyotex, taking full control. The deal terms were not disclosed, but Calliditas had previously acquired 62.7% in 2020 for about $24 million. Genkyotex's lead candidate setanaxib is set for a Phase 2b/3 trial in 2021.BenzingaCalliditas Takes 100% Control Of GenkyotexSwedish drugmaker Calliditas Therapeutics has completed a centralized squeeze-out offer to take 100% control of Genkyotex, making it a wholly-owned subsidiary delisted from Euronext. Calliditas initially acquired a 62.7% stake in Genkyotex in 2020 for approximately $24 million. Genkyotex's lead product candidate setanaxib, a first-in-class NOX inhibitor targeting fibrogenesis drivers, is advancing toward a Phase 2b/3 trial in primary biliary cholangitis and a Phase 2 proof-of-concept study in head and neck cancer.PR NewswireCalliditas announces acquisition of remaining Genkyotex minority sharesCalliditas Therapeutics announced the completion of a centralized squeeze-out offer, acquiring 100% of Genkyotex and delisting it from Euronext stock exchanges. This acquisition allows Calliditas to fully integrate Genkyotex's platform, including its lead candidate setanaxib, which is currently in Phase 3 trials for IgA nephropathy and has received FDA fast track designation for primary biliary cholangitis.PR NewswireCalliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D DayCalliditas Therapeutics announced at its R&D Day that it will advance setanaxib into a pivotal Phase 2/3 study for primary biliary cholangitis in the second half of 2021, pending FDA feedback, and a Phase 2 proof-of-concept study in head and neck cancer this year. The company also reported safety data from Part A of the Phase 3 NefIgArd study for its lead candidate Nefecon in IgA nephropathy, showing no adverse clinical effects related to weight gain, blood pressure, or HbA1c. Calliditas acquired a controlling stake in Genkyotex, the developer of the first-in-class NOX inhibition platform behind setanaxib, in Q4 2020.PR NewswirePositive Phase 1 results in high-dose setanaxib trialCalliditas Therapeutics announced positive Phase 1 data for its subsidiary Genkyotex's lead asset, setanaxib, demonstrating a favorable safety and pharmacokinetic profile at high doses up to 1600 mg/day. These results support the pursuit of pivotal Phase 2/3 clinical trials for primary biliary cholangitis (PBC) following interactions with the FDA. The company also indicated potential expansion into other kidney-related orphan diseases where inflammation and fibrosis are key factors.PR NewswireCalliditas announces final outcome of simplified mandatory offer to the shareholders of GenkyotexCalliditas Therapeutics announced the final outcome of its simplified mandatory offer for Genkyotex, resulting in Calliditas controlling 86.2% of Genkyotex's shares. The transaction involved Calliditas acquiring additional shares from remaining shareholders at EUR 2.80 per share, bringing its total holding to over 10 million shares. This acquisition solidifies Calliditas's majority control over the biopharmaceutical company Genkyotex.news.cision.comCalliditas announces final outcome of simplified mandatory offer to the shareholders of GenkyotexCalliditas completed a simplified mandatory offer to Genkyotex shareholders, acquiring 2,885,161 shares. The company now controls 86.2% of Genkyotex's share capital and voting rights. The offer was submitted on November 26, 2020, with the acceptance period ending December 11.PR NewswireInterim Report Q3, 2020Calliditas Therapeutics reported Q3 2020 results with no net sales and an operating loss of SEK 104.9 million, compared to a loss of SEK 52.6 million in Q3 2019. In August 2020, the company announced the acquisition of a majority 62.7% stake in Genkyotex SA, a French life science company specializing in NOX inhibition therapies, for €19.8 million, completing the transaction in November 2020. Following the quarter end, Calliditas announced positive topline results from Part A of its pivotal Phase 3 NefIgArd trial, with regulatory filings planned for Q1 2021 with the FDA and H1 2021 with the EMA.news.cision.comCalliditas closes acquisition of a controlling interest in Genkyotex SACalliditas closed an off-market acquisition of 62.7% of Genkyotex SA for €19.8M cash plus contingent rights. The deal includes a planned tender offer for remaining shares at €2.80 per share, with a squeeze-out expected if Calliditas holds over 90%.PR NewswireCalliditas closes acquisition of a controlling interest in Genkyotex SACalliditas Therapeutics AB has completed the acquisition of a 62.7% controlling stake in Genkyotex SA through an off-market block trade for €19.8 million in cash, having received clearance from the French Minister of Economy and Finance. The Swedish pharmaceutical company will now file a mandatory cash tender offer for the remaining shares at €2.80 per share, potentially followed by a squeeze-out if it acquires over 90% of outstanding shares. The total acquisition cost for 100% of Genkyotex is approximately €31.7 million, plus contingent rights up to €55 million tied to future regulatory approvals of setanaxib, Genkyotex's lead NOX inhibitor asset for fibrotic diseases.